Extension Study of Gelesis100 on Body Weight

NACompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 25, 2017

Primary Completion Date

December 8, 2017

Study Completion Date

December 15, 2017

Conditions
Overweight and Obesity
Interventions
DEVICE

Gelesis100 (2.25 g)

Three capsules of Gelesis100, each containing a 750 mg mixture of two food-grade materials: carboxymethylcellulose that is cross-linked with citric acid.

Trial Locations (16)

10065

Cornell Weill Medical College, New York

17822

Geisinger Health System, Danville

20097

IRCCS Policlinico San Donato, Milan

31008

University of Navarra, Pamplona

32205

Westside Center for Clinical Research, Jacksonville

43213

Aventiv Research, Columbus

45249

Radiant Research, Cincinnati

70808

Pennington Biomedical Research, Baton Rouge

78681

Texas Diabetes and Endocrinology, Round Rock

80045

University of Colorado, Aurora

92103

Arternis Institute for Clinical Research, San Diego

92780

Clinical Trial Investigators, Tustin

02118

Boston University Medical Center, Boston

182 00

Health & Care SRO, Prague

DK-1958

University of Cophenhagen, Copenhagen

00186

University of Rome, Rome

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gelesis, Inc.

INDUSTRY

NCT03021291 - Extension Study of Gelesis100 on Body Weight | Biotech Hunter | Biotech Hunter